A new study offers the first atomic-scale view of an interaction between the HIV capsid - the protein coat that shepherds HIV into the nucleus of human cells - and a host protein known as cyclophilin ...
Watch this dynamic webinar for valuable insights into characterizing the stability of an engineered adeno-associated virus (AAV) serotype under moderate thermal stress and physiological solution ...
The FDA has granted Fast Track designation to pevifoscorvir sodium, an oral capsid assembly modulator for chronic HBV.
The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...
Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, along with scientists from the Broad Institute of MIT and Harvard, will present ...
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...
High-quality HIV antigens for cutting-edge solutions. On February 18, 2025, Gilead Sciences (CA, US) announced a significant milestone: the US FDA accepted their New Drug Applications (NDAs) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results